West Nile virus infections projected from blood donor screening data, United States, 2003

被引:116
作者
Busch, MP
Wright, DJ
Custer, B
Tobler, LH
Stramer, SL
Kleinman, SH
Prince, HE
Bianco, C
Foster, G
Petersen, LR
Nemo, G
Glynn, SA
机构
[1] Blood Syst Res Inst, San Francisco, CA 94118 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] WESTAT Corp, Rockville, MD 20850 USA
[4] Amer Red Cross, Natl Testing & Reference Labs, Gaithersburg, MD USA
[5] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[6] Focus Diagnost, Cypress, CA USA
[7] Amer Blood Ctr, Washington, DC USA
[8] Ctr Dis Control & Prevent, Ft Collins, CO USA
[9] NHLBI, Bethesda, MD 20892 USA
关键词
D O I
10.3201/eid1203.051287
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
National blood donor screening for West Nile virus (WNV) RNA using minipool nucleic acid amplification testing (MP-NAT) was implemented in the United States in July 2003. We compiled national NAT yield data and performed WNV immunoglobulin M (IgM) testing in 1 WNV-epidemic region (North Dakota). State-specific MP-NAT yield, antibody seroprevalence, and the average time RNA is detectable by MP-NAT were used to estimate incident infections in 2003. WNV donor screening yielded 944 confirmed viremic donors. MP-NAT yield peaked in August with > 0.5% of donations positive for WNV RNA in 4 states. Peak IgM seroprevalence for North Dakota was 5.2% in late September. The average time viremia is detectable by MP-NAT was 6.9 days (95% confidence interval [CI] 3.0-10.7). An estimated 735,000 (95% Cl 322,000-1,147,000) infections occurred in 2003, with 256 (95% Cl 112-401) infections per neuroinvasive case. In addition to preventing transfusion-transmitted WNV infection, donor screening can serve as a tool to monitor seasonal incidence in the general population.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 31 条
  • [1] [Anonymous], 2006, SAS PROPR SOFTW REL
  • [2] Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City
    Biggerstaff, BJ
    Petersen, LR
    [J]. TRANSFUSION, 2002, 42 (08) : 1019 - 1026
  • [3] Screening the blood supply for west nile virus RNA by nucleic acid amplification testing
    Busch, MP
    Caglioti, S
    Robertson, EF
    McAuley, JD
    Tobler, LH
    Kamel, H
    Linnen, JM
    Shyamala, V
    Tomasulo, P
    Kleinman, SH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (05) : 460 - 467
  • [4] Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003
    Busch, MP
    Tobler, LH
    Saldanha, J
    Caglioti, S
    Shyamala, V
    Linnen, JM
    Gallarda, J
    Phelps, B
    Smith, RIF
    Drebot, M
    Kleinman, SH
    [J]. TRANSFUSION, 2005, 45 (04) : 492 - 499
  • [5] *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P281
  • [6] *CDCP, 2004, STAT SURV CONTR 2003
  • [7] Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P916
  • [8] Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1129
  • [9] Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: Analysis of 2003 data to inform 2004 decision making
    Custer, B
    Tomasulo, PA
    Murphy, EL
    Caglioti, S
    Harpool, D
    McEvoy, P
    Busch, MP
    [J]. TRANSFUSION, 2004, 44 (11) : 1547 - 1554
  • [10] Emerging infections, transfusion safety, and epidemiologic
    Dodd, RY
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) : 1205 - 1206